Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday. Source: f11photo/Shutterstock.com There’s loads of earning reports out today, as wel...
Shares of Kezar Life Sciences (NASDAQ:KZR) are up 66% in after-hours trading after reporting interim results from a phase 2 trial of its lupus candidate KZR-616. The company said that KZR-616, a a first-in-class selective immunoproteasome inhibitor, demonstrated clinically meaningfu...
KZR-616 demonstrates clinically meaningful benefit in patients with lupus nephritis, with 4 out of 5 patients achieving either a partial or complete renal response at end of treatment KZR-616 maintained a favorable safety and tolerability profile over the six-month treatment...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conferen...
Kezar is a biopharmaceutical company committed to developing breakthrough treatments for immune-mediated and oncologic disorders. Oxford Finance LLC (“Oxford”), a leading specialty finance firm that provides senior debt to life sciences ...
Target enrollment met in the MISSION Phase 2 trial evaluating KZR-616 for lupus nephritis First patient dosed in Phase 1 trial of KZR-261 for the treatment of advanced solid tumor malignancies Company to host virtual Investor and Analyst Day on Monday, November 15, 2...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET. ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the first patient has been dosed in KZR-261-101, a Phase 1 clinical trial evaluating K...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affair...
The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with this event. For further details see: Kezar Life Sciences (KZR) Corporate Overview
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...